TD Cowen raised the firm’s price target on Travere Therapeutics to $15 from $12 and keeps an Outperform rating on the shares. The firm updated its model and slightly decreasedtheir Q4 Filspari revenue estimate per the perannouncement and also decreased OpEx estimates to reflect managements recent commentary.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TVTX:
- Travere Therapeutics price target raised to $11 from $10 at Piper Sandler
- Travere Therapeutics announces anticipated 2024 milestones
- Travere Therapeutics sees 2023 net product sales from cont. ops. $40M
- Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Travere Therapeutics price target raised by $2 at H.C. Wainwright, here’s why
